Literature DB >> 32450186

Antinociceptive effects of nefopam modulating serotonergic, adrenergic, and glutamatergic neurotransmission in the spinal cord.

Joo Wung Chae1, Dong Ho Kang2, Yaqun Li1, Seung Hoon Kim2, Hyung Gon Lee2, Jeong Il Choi3, Myung Ha Yoon3, Woong Mo Kim4.   

Abstract

The present study investigated the effects of intrathecal nefopam on the pain behavior and on the extracellular levels of serotonin (5-HT), norepinephrine (NE), and glutamate in the spinal cord, in a rat model of pain induced by formalin. Nefopam was intrathecally administered 10 min prior to the formalin test to assess its antinociceptive effects. In another cohorts of animals, dihydroergocristine, yohimbine, or (RS)-α-Methylserine-O-phosphate (MSOP), a serotonergic, α-2 adrenergic receptor, or group III metabotropic glutamate receptor antagonist, respectively, were administered prior to the application of nefopam in the formalin test. Microdialysis studies were conducted to measure the extracellular levels of 5-HT, NE, and glutamate in the spinal cord following nefopam administration. Intrathecal nefopam reduced formalin-induced behavior in both phases of the test. The blockade of serotonergic or adrenergic receptors partially reversed the analgesic effects of nefopam in the first phase of the formalin test whereas MSOP reversed these effects in both phases. The microdialysis results revealed that intrathecal nefopam significantly increased 5-HT and NE levels and attenuated the formalin-induced release of glutamate in the spinal cord. Thus, the present data suggest that the increase in the extracellular levels of 5-HT and NE, and reductions in glutamate release in the spinal cord, may have contributed to the analgesic effects of nefopam.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glutamate; Microdialysis; Nefopam; Norepinephrine; Serotonin

Mesh:

Substances:

Year:  2020        PMID: 32450186     DOI: 10.1016/j.neulet.2020.135057

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Nefopam prescribing preferences in French hospitals: results of a survey.

Authors:  Thomas Schulz; Laure Lalande; Frederic Aubrun; Mikhail Dziadzko
Journal:  Pan Afr Med J       Date:  2022-03-15

2.  Systemically administered neurotensin receptor agonist produces antinociception through activation of spinally projecting serotonergic neurons in the rostral ventromedial medulla.

Authors:  Yaqun Li; Dong Ho Kang; Woong Mo Kim; Hyung Gon Lee; Seung Hoon Kim; Hyun Eung You; Jeong Il Choi; Myung Ha Yoon
Journal:  Korean J Pain       Date:  2021-01-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.